Andrew Messick

Andrew Messick serves as the Chief Financial Officer at Kymanox since April 2025. Prior to this role, Messick held the position of Chief Financial Officer at Sabai Global from September 2020 to April 2025, overseeing finance for a prominent provider of clinical research and biosafety services, which includes various subsidiaries. Messick also served as Chief Financial Officer for PeriGen from September 2017 to October 2019, where responsibilities included financial strategy and post-acquisition integration. Earlier experience includes a tenure as Vice President of Finance at WCG and Chief Financial Officer at Copernicus Group IRB, both contributing to financial leadership and strategic planning within the clinical research sector. Messick holds a Master’s degree in Accountancy and a Bachelor of Science in Business Administration from UNC Kenan-Flagler Business School.